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Abstract  
Low high-density lipoprotein (HDL) cholesterol levels are associated with an increased risk 
of coronary artery disease and myocardial infarction.  Experimental studies have identified 
several potential anti-atherogenic properties of HDL, including promotion of macrophage 
cholesterol efflux, endothelial nitric oxide stimulation, anti-inflammatory and anti-thrombotic 
effects.  These observations have lead to the important question of whether raising of HDL 
can reduce cardiovacular risk.   
Notably, recent studies have suggested that vascular effects of HDL can be highly 
heterogenous and are altered in patients with coronary disease or diabetes, that has been 
referred to as “HDL dysfunction”.  Moreover, studies using gene-targeted mice have 
indicated that genetic modifications leading to a similar increase of HDL cholesterol levels 
can either reduce (i.e. apoA1 transgene overexpression) or accelerate (i.e. SR-B1 deficiency) 
atherosclerosis, depending on the molecular target.    
These findings therefore suggest that HDL cholesterol levels alone are likely not sufficient as 
a readout for the vascular effects of HDL-targeted therapeutic interventions, since both, the 
vascular effects of on-treatment HDL as well as the underlying molecular mechanism used to 
elevate HDL cholesterol levels may represent critical determinants of the overall vascular 
effects of therapeutic interventions raising HDL-cholesterol levels.    
In summary,  low HDL cholesterol plasma levels remain associated with an increased 
cardiovascular risk.  However, the above findings suggest that careful clinical trial 
programms are needed to determine, which HDL raising therapeutic interventions may 
indeed exert vasoprotective effects.     
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Coronary artery disease remains the leading cause of death in the developed countries.  
Moreover, the risk of cardiovascular complications, such as myocardial infarction, remains 
substantial despite current optimal medical therapy in patients after an acute coronary 
syndrome (1).   Therefore, novel approaches to reduce cardiovascular risk are intensely 
examined, and HDL has received great attention as a potential novel therapeutic target. 
Low levels of HDL are associated with an increased cardiovascular risk (2).  Moreover, 
several mechanisms have been identified whereby HDL may exert anti-atherosclerotic 
effects.  Initially, reverse cholesterol transport by HDL has been suggested as a potential anti-
atherosclerotic mechanism of HDL (3) and the molecular mechanisms whereby HDL 
promotes macrophage cholesterol efflux have been identified, in particular the ABCA-1 and 
ABCG-1 transporters (4).  Later it was shown that HDL exhibits direct effects on vascular 
cells, in particular endothelial cells, that could represent anti-atherogenic properties of HDL, 
such as the capacity of HDL to stimulate endothelial cell nitric oxide (NO) production, to 
promote endothelial repair and to exert anti-inflammatory and anti-thrombotic effects (5-7).   
Importantly, however, more recent evidence has suggested that the effects of HDL on 
macrophage cholesterol efflux and in particular the endothelial effects of HDL can be highly 
heterogeneous, and are altered in patients with coronary disease or diabetes, that has also 
been referred to as “HDL dysfunction”.   In this respect, Khera et al. have reported that the 
cholesterol efflux capacity of apoB-depleted serum (as a measure of the capacity of HDL to 
accept cholesterol from macrophages) was inversely related to carotid intima-media thickness 
and the likelihood of angiographic coronary artery disease that was independent of the HDL 
cholesterol levels (8).  We have observed that that the capacity of HDL to stimulate 
endothelial NO production or endothelial repair mechanisms is substantially impaired in 
patients with coronary disease or diabetes (7, 9).  HDL isolated from healthy subjects 
sunstantially stimulated endothelial cell NO production and accelerated endothelial repair in 
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vivo, whereas no such effects were observed, when HDL was isolated from patients with 
coronary disease or diabetes (7, 9).   The underlying mechanisms need to be further defined, 
but likely include increased lipid oxidation of HDL due to a reduced HDL-associated 
paraoxonase-1 activity, an enzyme that protects HDL from lipid oxidation.   Moreover, HDL 
is a highly complex lipoprotein that has likely more than 70 associated proteins, as identified 
by proteomics analysis (10) and consists likely of more than 1000 different lipid species 
(Figure).  Therefore, the vascular effects of HDL are not necessarily predicted by the HDL 
cholesterol levels, since cholesterol is only one lipid component of the lipoprotein.  These 
observations also raise the possibility that vascular effects of on-treatment HDL may be an 
important determinant of the overall vascular effects of an HDL-raising intervention.    
Moreover, it has been realized that the HDL metabolism, i.e. HDL synthesis, transfer and 
uptake mechanisms, are complex, and HDL cholesterol levels can therefore be raised by 
multiple interventions, either promoting HDL synthesis, preventing transfer of HDL 
components (such as cholesterol ester transfer protein – CETP – inhibition) or by prevention 
of uptake of HDL cholesterol (such as SR-BI inhibition).   Interestingly, experimental studies 
in mice have suggested that transgenic overexpression of human apolipoprotein-A-I, the 
major protein component of HDL,  increased HDL cholesterol levels and reduced 
development of atherosclerosis (11).  In contrast, however, raising HDL cholesterol by 
inhibition of the Scavenger receptor class B type I (SR-BI),  that mediates uptake of HDL-
cholesterol and cholesteryl ester in the liver and steroidogenic tissues,  resulted also  in 
increased HDL cholesterol levels, but at the same time was associated with an accelerated 
atherosclerosis development in mice (12).   Notably, the SR-BI receptor is also expressed on 
endothelial cells, and likely mediates several of the endothelial-protective effects of HDL, 
such as stimulation of endothelial cell NO production and endothelial repair (5, 13).  Raising 
HDL cholesterol by SR-BI inhibition may therefore also inhibit the endothelial-protective 
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mechanisms exerted by HDL.   These studies in gene-targeted mice suggest that interventions 
that increase HDL cholesterol levels can either reduce or increase atherosclerosis 
development, depending on the underlying molecular mechanism that leads to elevation of 
HDL cholesterol levels. 
The above observations suggest that HDL cholesterol levels alone are likely not sufficient as 
a therapeutic target.  Both, the on-treatment vascular effects of HDL as well as the underlying 
molecular mechanism leading to increased HDL cholesterol levels are likely important 
determinants of the overall vascular effects of an HDL-choelsterol raising therapeutic 
intervention.  Therefore, careful clinical trials are needed for HDL-raising therapies, to 
determine the overall cardiovascular effects of such interventions.  At present, several clinical 
trial programms are performed, using different CETP-inhibitors (dalcetrapib, anacetrapib, 
evacetrapib), nicotinic acid/laropiprant (HPS-3 study) or reconstituted forms of HDL. 
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Figure legend 
Figure  
HDL consists of more than seventy proteins and likely more than 1000 lipid species, 
illustrating the complexity of this lipoprotein, that is greater as has been previously 
considered.  This explains why measurement of HDL cholesterol levels alone are likely not 
sufficient to predict vascular effects of HDL-raising interventions.   
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